Genome Editing Market Segmentation:
Technology Segment Analysis
Based on the technology, the CRISPR-Cas9 segment in the genome editing market is expected to hold the largest share of 67.5% by the end of 2034. The segment’s growth is highly attributed to affordability, scalability, and precision, in comparison to alternative options, including TALENs and ZFNs. Besides, the technology is widely adopted, and the reason originates from therapeutic breakthroughs, such as FDA-accepted treatments, including Casegevy for sickle cell disorder, along with its extended applications in biomanufacturing and agriculture. Additionally, the technology’s modular design has enabled speedy personalization to diminish development duration by 46%, thus suitable for uplifting the segment.
End user Segment Analysis
Based on the end user, the pharma and biotech companies segment in the genome editing market is projected to hold the second-largest share of 57.2% during the forecast timeline. The segment’s upliftment is extremely attributed to tactical partnerships and an increase in R&D investment. These are leading with commercialization efforts, with CRISPR-related therapies, including Vertex, deliberately generating USD 625 million in sales as of 2023. In addition, the segment’s development is further reflected by 70% of R&D funding effectively targeting oncology and chronic disorders, and vertical implementation initiatives, such as Thermo Fisher’s USD 1.9 billion acquisition of viral vector manufacturing, thus boosting the overall segment.
Our in-depth analysis of the global market includes the following segments:
|
Segment |
Subsegment |
|
Technology |
|
|
End user |
|
|
Application |
o Oncology o Rare Diseases
o Gene-Edited Crops
o Biofuels o Biomanufacturing |
